(NASDAQ: TXG) 10x Genomics's forecast annual revenue growth rate of 3.66% is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 9.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.42%.
10x Genomics's revenue in 2026 is $642,823,000.On average, 19 Wall Street analysts forecast TXG's revenue for 2026 to be $79,128,468,605, with the lowest TXG revenue forecast at $75,976,820,499, and the highest TXG revenue forecast at $83,703,276,821. On average, 19 Wall Street analysts forecast TXG's revenue for 2027 to be $84,872,209,945, with the lowest TXG revenue forecast at $79,500,227,664, and the highest TXG revenue forecast at $92,154,088,423.
In 2028, TXG is forecast to generate $91,682,682,606 in revenue, with the lowest revenue forecast at $83,493,763,124 and the highest revenue forecast at $101,275,599,359.